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Abstract 
 
Lipoxygenases (LOX) and cycloxygenase (COX) are the main enzymes for PUFA-metabolism 
to highly bio-active prostaglandins, leukotrienes, thromboxanes, lipoxines, resolvins and 
protectins. LOX and COX pathways are important for the regulation of pro-inflammatory or 
pro-resolving metabolite synthesis and metabolism for various inflammatory diseases such 
as atopic dermatitis (AD). In this study we determined PUFAs and PUFA-metabolites in 
serum as well as affected and non-affected skin samples from AD-patients and the dermal 
expression of various enzymes, binding proteins and receptors involved in these LOX and 
COX pathways. Decreased EPA and DHA levels in serum and reduced EPA level in affected 
and non-affected skin were found; in addition n3/n6-PUFA ratios were lower in affected and 
non-affected skin and serum. Mono-hydroxylated PUFA-metabolites of AA, EPA, DHA and 
the sum of AA, EPA and DHA metabolites were increased in affected and non-affected skin. 
COX1 and ALOX12B expression, COX and 12/15-LOX metabolites as well as various lipids, 
which are known to induce itch (12-HETE, LTB4, TXB2, PGE2 and PGF2) and the ratio of 
pro-inflammatory vs pro-resolving lipid mediators in non-affected and affected skin as well 
as in the serum of AD patients were increased, while n3/n6-PUFAs and metabolite ratios 
were lower in non-affected and affected AD-skin. Expression of COX1 and COX-metabolites 
were even higher in non-affected AD-skin. To conclude, 12/15-LOX and COX pathways were 
mainly upregulated, while n3/n6-PUFA and metabolite ratios were lower in AD-patients skin. 
All these parameters are a hallmark of a pro-inflammatory and non-resolving environment in 
affected and partly in non-affected skin of AD-patients.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Introduction 
 
Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease, characterized by 
dryness, eczematous skin lesions, pruritic excoriations and lichenification 1, 2. In the 
background disturbed skin barrier, altered immune response of various immune cells, mainly 
lymphocytes and eosinophils, leading to a Th1 / Th2 shift, defects in permeability barrier 
functions and IgE mediated mechanisms all play a role1,2. Although external factors are 
pivotal in atopy development, studies confirming the association of AD with various 
polymorphisms as reviewed in 3, also pointed on the importance of genetic factors.  
 
Polyunsaturated fatty acids (PUFA) and especially their bioactive metabolites the eicosanoids 
and docosanoids are involved in the modification of various aspects of inflammatory 
responses in AD (reviewed in 4, 5). Arachidonic acid (AA), docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) are the major precursors of a large variety of lipid mediators 
with pro-inflammatory (prostaglandins, leukotrienes, thromboxanes) or pro-resolving 
(lipoxins, resolvins, protectins, maresins) activity 6. Cyclooxygenase (COX) and 
lipoxygenases (LOX) pathways and further enzymes such as prostaglandin-synthases, 
thromboxane synthase and leukotriene-synthases are involved in bioactive eicosanoid / 
docosanoid synthesis during inflammatory conditions of allergic diseases 5, 7-10. Various 
eicosanoids / docosanoids were shown to be potent activators of GPCRs, such as leukotriene 
B4 (LTB4) receptors (BLT1 and 2), cysteinyl-leukotriene receptors (CYSLTR 1 and 2), 
thromboxane receptor (TXB2), prostaglandin receptors for prostaglandin D2 (PGD2) (DP1 
and 2), prostaglandin E2 (PGE2) (EP1, 2, 3 and 4), prostaglandin F2 (PGF2) (FP), lipoxin 
receptor (LXA4R) as well as activators of nuclear hormone receptors 4, 6. Mainly the 
peroxisome proliferator-activated receptors (PPARα and PPARγ) are activated by fatty acids 
and eicosanoids / docosanoids 11, 12. PPARα plays an important role during skin development, 
maturation of epidermal barrier and sebocyte activation 13, 14, while PPARγ seems to be 
involved in sebaceous gland differentiation and immunoregulatory processes 15-17. Ligand 
trafficking is mediated via fatty acid binding proteins (FABP), which are intracellular 
transporters and attractors of various fatty acids. FABP4 seems to be associated with PPAR-
mediated signaling and FABP7 with attraction of DHA 18, 19.  
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In this study we investigated eiconsanoid- / docosanoid-mediated signaling via enzyme, 
receptor and binding protein expression using transcriptomic as well as eicosanoid / 
docosanoid levels using lipidomic techniques in the skin of healthy volunteers and affected / 
non-affected skin of AD patients. We used and applied an optimized lipidomic method for 
analyzing micro-amounts of available skin biopsies. Our aim was to get an overview how 
eicosanoid / docosanoid signaling is altered in atopic dermatitis and based on our results to 
further plan targeted therapy for atopic dermatitis using selected agonists / antagonists for 
receptors and / or enzymatic inhibitors of various involved enzymes. 
 
Materials and methods 
 
Sample collection 
Skin biopsy specimens were taken after obtaining informed consent in involved areas from 
six patients with AD (two male and four female patients; average age 31 years; according to 
the declaration of Helsinki, and from six non-atopic healthy volunteers (two male and four 
female individuals; average age 30 years) characterized by the absence of personal or family 
history of atopic disease. In case of AD patients, one biopsy of affected skin and one biopsy 
of non-affected skin were taken from each patient. Specimens were immediately frozen in 
dry ice and stored at -70 °C until RNA isolation or HPLC analysis. For HPLC-MS analysis just 
3 patients were included, due to limited available skin tissue (average age 28, SCRORAD 
42.5, average total IgE 4126 KU/L and specific IgE 49 KU/L, 1 male / 2 female, two patients 
are of extrinsic and one patient of combined intrinsic / extrinsic phenotype). Additionally, 
serum samples were drawn from the same patients and healthy controls and were kept at -
70 °C until analysis. For preparation of the serum samples blood was allowed to clot for 10 
minutes at room temperature and spun down at 1500 g and 4°C. The serum was aliquoted 
to 250 µl portions and stored at -80°C until further analysis. Ethical approval for the study 
was obtained from the local ethics committee of the University of Debrecen in Hungary 
(EA1/168/06). 
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Analysis of mRNA expression  
Skin samples were homogenized with QIAGEN Tissue Lyser in Tri reagent solution 
(Molecular Research Center Inc., Cincinnati, OH, USA) using previously autoclaved QIAGEN 
metal beads and total RNA was isolated according to the manufacturer’s guidelines. The 
concentration and purity of RNA were measured by means of NanoDrop spectrophotometer 
(Thermo Scientific, Bioscience, Budapest, H). RNA quality was checked using agarose gel-
electrophoresis. For real-time quantitative PCR (QRT-PCR) total RNA was reverse transcribed 
into cDNA using the SuperScript II First Standard Synthesis System (Invitrogen, Life 
Technologies Magyarország Kft., Budapest, H). QRT-PCR was carried out in triplicates using 
pre-designed MGB assays ordered from Applied Biosystems (Applied Biosystems, Applera, 
Budapest, H) using an ABI Prism 7900. Relative mRNA levels were calculated with either the 
comparative CT or standard curve methods normalized to cyclophilin A mRNA. Sequence 
Detector Software (version 2.1) (Applied Biosystems) was utilized for data analysis, and 
relative fold induction was determined by the comparative threshold cycle method. 
 
Immunohistochemistry 
The tissue cryo-sections (5 µm) were incubated with antibodies against the human ALOX12B 
(Abgent, Oxfordshire, UK) or COX1 (5F6/F4, Abcam plc, Cambridge, UK), followed by 
biotinylated goat anti-rabbit IgG and anti-mouse IgG, respectively (both DAKO Diagnostika, 
Hamburg, D). Nonspecific binding was blocked with 5% bovine serum albumin (BSA) in PBS 
for 30 min at room temperature. Negative controls were performed by omitting the primary 
antibody. Detection was performed using Dako REAL™ Detection System Alkaline 
Phosphatase/RED (DAKO) and by hematoxylin counterstaining (Merck, Darmstadt, D). 
Finally, images were taken at x100 magnification using the Axioplan light microscope 
equipped with a AxioCamHR and Axiovision analysis software (Carl Zeiss, Jena, D).  
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HPLC-ESI-MS-MS analysis of free fatty acids and eicosanoids and docosanoids in 
skin and serum 
The previously described procedure for the HPLC-ESI-MS-MS method was followed with 
minor modifications 7, 20, 21. 
 
Sample preparation. The whole analytical sample preparation procedure is based on an 
established method used for retinoid quantification 22. In summary, to 50 μl of serum or 50 
mg of a skin biopsy (if less that 50 mg of skin biopsy was present, water was added to yield 
50 mg of sample weight for our standardized extraction protocol), 150 μl acetonitrile was 
added and the skin samples were cut with scissors in small pieces on ice. These mixtures 
were shaken for 3 min, the precipitated protein was centrifuged at 13.000 rpm, 4°C for 6 
min, 130 μL of the resulting supernatant was spiked with 10 μl isotope supernatant mix 
containing (prostaglandin D2 (PGD2) (D4), 5-hydroxy-eicosatetraenoic acid (5-HETE) (D8), 
15-hydroxy-eicosatetraenoic acid (15-HETE) (D8) and 9-hydroxy-octadecadienoic acid (9-
HODE) (D4), each at a concentration of 10 μg/ml as the internal control), evaporated in 
Eppendorf reaction vials with an Eppendorf concentrator at 30°C for 60 min until the sample 
volume was ~10 µl. The Eppendorf concentrator was vented with highly pure argon to 
prevent degradation of eicosanoids and docosanoids. The semi-dried extract was 
resuspended with approximately 25 μl of HPLC solvent A [64.3% water (water, Chromasolv 
Plus from Sigma-Aldrich, H) and 35.5% acetonitrile (Merck KGaA, D) and 0.2% formic acid 
(Fluka, H)] to yield exactly 35 μl, then vortexed (15 sec), shaken (3 min) and transferred 
into micro-injection inserts vials (Waters, H). These glass vials with the 35 μl extract were 
transferred into brown screw top vials with PTFE / silicone septa sample (Waters, H) and 
placed in the pre-cooled (15°C) autosampler of the Waters 2695XE separation module and 
immediately analysed. 
 
Chromatographic system. The HPLC system consisted of a Waters 2695XE separation 
module (Waters, H) including a gradient pump, autosampler, degasser and a heated column 
compartment. A MS-MS detector with an ESI ionizing option was used (Micromass Quattro 
Ultima PT from Waters, UK) as a detector. The system was controlled via the MassLynx 
software (Waters, H). 
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HPLC conditions. The eluents were degassed in the Waters 2695XE separation module 
prior to mixing, then passed through an in-line filter (1-2 μm; Knauer, D) before reaching 
the analytical column (LiChroCART, 125 X 2 mm; Superspher 100, RP-18, endcapped) from 
Merck KgaA (D) embedded in the column compartment. A multilinear gradient was formed 
from solvent A (see above) and solvent B (methanol; Merck KGaA D). The gradient 
consisted of the following steps: 0.0 min 20% B, 3.0 min 20 % B, 5.0 min 60 % B, 15.0 min 
100 % B, 15.9 min 100 % B and 16.0 min 5 % B. The flow rate was adjusted to 0.4 ml/min 
and the column was heated to 40°C. From the same biological extract, 11 μl for each HPLC 
analysis was used. This step was performed twice using the same HPLC conditions and two 
different MS-MS analysis options (method A or B) for optimized resolution and quantification 
of a larger variety of analytes. 
 
MS options. The Micromass Quattro Ultima PT was controlled via the MassLynx software. 
Argon with an inlet pressure of 0.8 bar was used. ESI (electro spray ionization source, 
Waters, H) was vented by nitrogen continuously produced by the nitrogen generator (Peak 
Scientific NM30 Nitrogen generator) including compressor (Waters, H) with the inlet flow set 
at 3.6 e-3 mbar. 
 
Multiple reaction monitoring settings: ESI, with a negative ESI – setting, was performed with 
the HPLC eluent following the ion source temperature of 85°C. The desolvation gas flow was 
780 l/h, the desolvation temperature was 400°C, the cone gas flow was 10 l/h, the capillary 
current was 3 μA, and the cone voltage was 50 V. Aperture voltage was set at 0 V and the 
RF lens voltage was set at 35 V (for 1) and 0.2 V (for 2). The analyzer settings were LM1 
resolution 14.5; HM1 resolution 14.5; Ion energy 1 0.7; entrance –1; collision 0 (collision 
parameters are set for each substance at the MS – method parameters); exit 2; LM2 
resolution 14.5; HM2 resolution 14.5; Ion energy 25.0 and a multiplier energy of 650 V. 
 
Multiple reaction monitoring settings for PUFA, eicosanoids/docosanoids quantification, 
retention times, collision energy, used method, time segments, correlation coefficient, 
individual recoveries as well as inter-day and intra-day -variations are listed in 
supplementary table 1. 
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Standard solutions. Stock solutions of the PUFAs, eicosanoids and docosanoids were 
prepared by dissolving the solutions obtained from Cayman-Chemicals (Tallin, EST), BioMol 
International (Kastel-Med KFT, Budapest, H), Sigma-Aldrich (Budapest, H), Larodan Lipids 
(Malmö, S) and Dr. Charles Serhan (Harvard University, MD, USA) with methanol to yield a 
final concentration of 10 μg/ml. All stock solutions were stored in darkness at -80°C. The 
reference PUFAs, eicosanoids and docosanoids were used for the assay validation. 
 
Quantification. Individual eicosanoids and docosanoids were quantified based on the 
determination of the “Area Under the Curve” (AUC) and compared with the AUC of standard 
compounds. To ensure optimal extraction and precision for quantification isotope labelled 
standard compounds were used (PGD2 (D4), 5-HETE (D8), 15-HETE (D8) and 9-HODE (D4)) 
and retention times and extraction efficiency based on an average of all four added isotopes 
was calculated and adjusted. This analytical procedure was established for liquids and tissue 
analysis. 
 
Statistics 
LC-MS data are shown as mean of three individual measurements and standard error mean 
values per data point. Values which were determined under the quantification limit (0.2 
ng/ml (or g)) were replaced with a value of half of the detection limit (0.1 ng/ml (or g)) for 
further calculation of statistics as well as ratios and sums. For PCR data each data points 
stands for 6 subjects. Statistical analysis was performed using the program SPSS 16.0 (SPSS 
Inc., Chicago, IL, USA). A P value of <0.05 was considered to be significant using student t-
test for independent samples.  
 
Results 
 
Increased AA levels in affected and non-affected skin of AD-patients and reduced 
n3/n6-PUFA ratios in skin of AD-patients: Initially, we examined the levels of free 
PUFAs in skin from healthy as well as affected and non-affected skin of AD-patients. AA 
levels were increased in non-affected (2.0-fold) and affected skin (1.8-fold) of AD-patients, 
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while no alteration was observed in AD-patients serum. EPA levels in skin and serum were 
comparable and serum levels of DHA were lower in AD-patients serum (Table 1 and 2, 
Figure 1). Ratios of n3/n6-PUFA such as EPA/AA and DHA/AA were also lower in non-
affected and affected skin as well as in serum of AD-patients (Figure 2). 
 
Increased levels of PUFA-hydroxy-metabolites in the AD-patients skin: Focusing 
on hydroxy-metabolites from PUFAs, we found that the levels of AA-hydroxy-metabolites, 
the hydroxy-eicosatetraenoic acids (HETEs), were increased in non-affected (2.5-fold) and 
affected skin (4.5-fold) of AD-patients as well as increased in AD-serum (2-fold). Hydroxy-
metabolites of EPA, the hydroxy-eicosapentaenoic acids (HEPEs), were just increased in the 
affected skin (1.6-fold) of AD-patients and comparable in AD-patients serum. Hydroxy-
metabolites of DHA, the hydroxy-docosahexaenoic acids (HDHAs), were increased in non-
affected (1.8-fold) and affected skin (6.5-fold) of AD-patients, while they were decreased 
(0.3-fold) in AD-serum.  
 
The ratios of HEPEs/HETEs were reduced in both non-affected and affected skin of AD-
patients and slightly decreased in AD-patients serum. Ratios of HDHAs/HETEs were also 
reduced in non-affected AD-patients skin and remained unchanged in affected skin and 
decreased in serum of AD-patients (Figure 2).  
 
Increased concentrations of PUFA-metabolites in the skin of AD-patients: Next, 
we focussed on the sum of AA-metabolites (AA-met) as well as DHA-metabolites (DHA-met) 
which were both increased in non-affected (AA-met: 3.1-fold; DHA-met: 1.8-fold) and 
affected skin (AA-met: 2.9-fold; DHA-met: 4.0-fold) of AD-patients, while just for the AA-
metabolites the serum levels were increased (1.7-fold) and DHA-metabolites were even 
decreased (0.3-fold). EPA-metabolites (EPA-met) remained comparable in AD-patients 
serum and were increased (2.2-fold) in affected skin of AD-patients. 
 
To further evaluate the ratios between the PUFAs, we calculated ratios of EPA-, DHA- and 
AA-metabolites. The ratios of AA-metabolites/AA, EPA-metabolites/EPA and DHA-
metabolites/DHA were increased in affected skin, while AA-metabolites/AA and DHA-
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metabolites/DHA were just increased in non-affected skin of AD-patients (Figure 2). Serum 
levels were just increased for AA-metabolites/AA, EPA-metabolites/EPA, while DHA-
metabolites/DHA were even decreased. Ratios of EPA-metabolites/AA-metabolites and DHA-
metabolites/AA-metabolites were reduced in non-affected skin of AD-patients, while DHA-
metabolites/AA-metabolites even increased in affected skin of AD-patients. The serum ratios 
of EPA-metabolites/AA-metabolites remained unchanged and DHA-metabolites/AA-
metabolites were lower (Figure 2). 
 
Increased levels of 5-lipoxygenase-derived metabolites in affected skin of AD-
patients: When focussing on the synthesis pathways, we first evaluated 5-lipoxygenase 
metabolism (ALOX5, 5-LOX), which is the key enzyme in the synthesis of mainly pro-
inflammatory leukotrienes. The expression of ALOX5 was not altered in AD-patients skin, 
while 5LOX-activating protein (FLAP) and leukotriene hydroxylase (LTA4H) were less 
expressed in affected skin (FLAP: 0.3-fold; LTA4H: 0.4-fold) of AD-patients (Figure 3, 
Supplementary Table 2). The expression of leukotriene receptors BLT1 was strongly 
increased in non-affected skin (2.1-fold) while CYSTL2 was reduced in non-affected (0.1-
fold) and affected (0.2-fold) skin of AD-patients skin.  
 
Surprisingly, the sum of the 5-LOX metabolites and LTB4 was just significantly increased in 
affected skin of AD-patients vs healthy or non-affected skin and even significantly decreased 
in AD-patients serum (Figure 2 and Table 2). 
 
8-Hydroxylation-pathway metabolites increased in affected and non-affected 
skin of AD-patients: Next, we calculated the sum of 8-hydroxylation-pathway metabolites 
which were just significantly increased in affected skin (3.1-fold) of AD-patients, while serum 
and affected skin levels remained non-significantly altered (Figure 2).  
 
Increased 12/15-LOX pathways in skin and serum of AD-patients: To assess the 
dermal expression profiles of the 12/15-lipoxygenases we focussed on ALOX12B 
(arachidonate lipoxygenase 12B) and ALOXE3 (arachidonate lipoxygenase 3), which were 
both significantly increased in non-affected (ALOX12B: 2.5-fold; ALOXE3: 2.4-fold) and 
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affected AD-skin (ALOX12B: 3.7-fold; ALOXE3: 3.0-fold) in comparison to healthy skin 
(Figure 3, Supplementary Table 2).  
 
The enhanced ALOX12B gene expression in skin of AD-patients was further verified at the 
protein levels using immunohistochemical stainings (Figure 4). In the skin of AD-patients 
hyperplasia and thickening of epidermis was evident and cell infiltration was prominent in 
comparison to the healthy control. Thereby, the histological features of atopic dermatitis are 
more distinctive in affected than in non-affected skin. The documented dermal infiltration is 
characterized by a perivascular pattern in non-affected skin, whereas affected AD skin 
possesses a rather diffuse distribution of infiltrating cells. 
 
AD skin featured a remarkably higher ALOX12B protein expression compared to healthy skin 
(Figure 4), with strong staining intensities in keratinocytes (marked by the black arrow) and 
in dermal infiltrating cells (marked by the green arrow). The increased epidermal thickness 
and degree of infiltration in affected vs. non-affected skin was associated with a higher 
ALOX12B protein expression. 
 
Skin levels originating from 12-LOX metabolism displayed a tendency to increase in non-
affected (2.6-fold) and affected skin (2.1-fold) of AD-patients, while the sum of 15-LOX 
metabolites was significantly increased both in non-affected (1.6-fold) and affected skin 
(6.1-fold) of AD-patients. 
 
Upregulated cyclooxygenases (COX)-mediated signaling pathway in AD-patients: 
Cyclooxygenases are the major enzymes for prostaglandin synthesis. The expression of 
COX1 was increased both in non-affected skin (9.4-fold) as well as affected skin (6.0-fold) of 
AD-patients (Figure 2). Expression of prostaglandin E synthase (PGES) was strongly 
decreased in non-affected skin (<0.01-fold) of AD-patients, while it was increased in 
affected skin (3.6-fold) of AD-patients (Figure 3, Supplementary Table 2). 
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To confirm the increased COX1 gene expression also at the level of protein synthesis we 
performed immunohistochemistry using whole skin samples (Figure 4). COX1 was broadly 
distributed throughout the AD lesions, which due to the epidermal thickening of AD skin, 
resulted in a remarkably higher COX1 protein expression in the epidermis (marked by the 
black arrows) than observed in healthy skin. Lesional skin of AD-patients is characterized by 
a massive infiltration of inflammatory cells involved in disease pathology (reviewed in 2). A 
proportion of infiltrating cells expressed COX1 thereby augmenting the COX1 protein amount 
in AD lesions (marked by the green arrow). Interestingly, the percentage of COX1 
expressing infiltrating cells seems to be higher in affected than in non-affected skin.  
 
In agreement with the expression and protein levels the sum of COX-metabolites was 
significantly increased in non-affected (3.6-fold) and in affected skin (2.1-fold) of AD-
patients.  
 
Pro-inflammatory vs pro-resolving lipid mediators. For further evaluation, we formed 
and calculated functional clusters of eicosanoids / docosanoids according their biological 
mediated activities. Firstly, we summarised the sum of pro-inflammatory mediators (LTB4, 
leukotriene C4 (LTC4), PGD2, PGE2, PGF2, 15-deoxy-Δ12,14-prostaglandin D2 
(d15d12PGD2), thromboxane B2 (TXB2) and 5-oxo-eicosatetraenoic acid (5-KETE)) as 
displayed in Figure 2A and calculated a ratio versus the sum of pro-resolving lipid mediators 
(lipoxin A4 (LXA4), lipoxin B4 (LXB4), resolvin D1 (RvD1), resolvin D2 (RvD2), protectin D1 
(PD1), maresin (MAR)). This ratio was increased in non-affected skin (1.5-fold) and even 
stronger in affected skin (2.3-fold) of AD-patients as well as a strong increase (4.8-fold) was 
observed in serum of AD-patients vs. healthy volunteers (Figure 2A).  
 
Reduced expression of peroxisome proliferator-activated receptors (PPAR) and 
PPAR-target gene expression:  
 
The expression of PPARα and γ was significantly decreased in the affected skin (PPARα: 0.5-
fold; PPAR γ: 0.2-fold) of AD-patients. While the expression of PPAR-target genes like 
RETSAT and CD36 displayed a tendency of reduced expression in affected skin, the 
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expression of fatty acid binding proteins (FABPs) was not altered, just a tendency of reduced 
expression was observed in the affected skin of AD-patients (Figure 3, Supplementary Table 
2). To assess the presence of possible PPAR activators, we calculated the sum of PPAR-
ligands, such as d15d12PGJ2, prostaglandin J2 (PGJ2), PGD2, 5-KETE, 12-oxo-
eicosatetraenoic acid (12-KETE), 15-oxo-eicosatetraenoic acid (15-KETE), 13-oxo-9,11-
octadecadienoic acid (13-KODE) and 4-hydroxy-docosahexaenoic acid (4-HDHA). We 
calculated a tendency of increased levels in affected skin found for PGD2, 12-KETE, 15-KETE 
and 13-KODE, while for PGJ2 and even 4-HDHA a significant increase was found in affected 
skin of AD-patients (Table 2). Sums of these ligands were just significantly higher in affected 
skin vs healthy skin (2.6-fold) (Figure 2E). 
 
The expression of the peroxisome proliferator-activated receptors (PPARs) was significantly 
decreased for PPARα and γ in affected skin (PPARα: 0.5-fold; PPAR γ: 0.2-fold) of AD-
patients. The expression of fatty acid binding proteins (FABPs) was not altered, just a 
tendency of reduced expression was observed in affected skin of AD-patients. Other PPAR-
target genes such as RETSAT and CD36, besides FABP4, displayed also a tendency of 
reduced expression in affected skin (Figure 3, Supplementary Table 2). 
 
Discussion: 
 
Atopic dermatitis is a chronic inflammatory skin disease with a prominent involvement of 
eicosanoids / docosanoids 7, 8, 23-27. In this study we made a comprehensive screening of 
these eicosanoids and docosanoids as well as expression of eicosanoid/docosanoid 
metabolizing enzymes, binding proteins and receptors in affected and non-affected skin of 
AD-patients compared to skin of healthy volunteers. We observed; a) Strong increase of 
various eicosanoids and docosanoids from COX and 5-, 12- and 15-LOX and 8-hydroxylation 
pathways in affected and surprisingly partly also in non-affected AD-skin. b) Increased levels 
of n6-PUFA-derived major itch-mediators such as LTB4, TXB2, 12-HETE, PGE2 and PGF2, 
which are partly even higher in non-affected skin of AD-patients. c) An additional feature 
was the reduced n3/n6-PUFA as well as various n3/n6-PUFA metabolite ratios in affected 
and non-affected skin of AD-patients. d) Strongly increased itch-mediators and pro-
inflammatory pathways in non-affected skin of AD-patients. e) Reduced PPAR-mediated 
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signaling despite the presence of increased PPAR-ligands in affected skin of AD-patients and 
f) affected skin specific increased LTB4 levels. These results altogether confirm and support 
a chronic inflammatory condition in atopic dermatitis. 
 
Previous studies by our groups determined strong reduced retinoid mediated signaling in 
skin of AD-patients 28. It was also observed in this previous study, that selected receptors 
and enzymes were strongly upregulated even in the non-affected skin of AD patients 28. 
Increased inflammatory signaling by reduced or increased retinoid receptor mediated-
pathway signaling in the skin is of high importance and influx of inflammatory cells such as 
leukocytes, macrophages and lymphocytes thereby result in increased 
eicosanoid/docosanoid mediated signaling due to high expression of various 
eicosanoid/docosanoid metabolizing enzymes, binding proteins and receptors in these 
inflammatory cells 29-35. Influx of inflammatory cells in affected and non-affected skin areas 
are also the major triggers for initiation and maintenance of the chronic inflammation 
present in AD 10 and reviewed in 2, 36.  
 
Surprisingly, expression of pro-inflammatory eicosanoid/docosanoid synthesis enzymes 
ALOX12B and COX1 were strongly increased in non-affected skin of AD-patients. Major itch-
mediators TXB2, LTB4, 12-HETE, PGE2 and PGF2 as well as the major itch-receptor BLT1 10, 
37-41 were highly present and expressed in affected and even higher expressed and present 
in non-affected skin of AD-patients, supporting the clinical findings that in AD patients 
itching is a general feature and not a part of local inflammation. Our results also revealed 
that even in the non-affected skin an inflammatory background is present as indicated by 
upregulated levels of various eicosanoids and docosanoids and involved synthetic pathways 
as well as influxed inflammatory cells. In the non-affected skin, no skin specific AD-
phenotype could be observed because most likely this skin specific AD-phenotype is 
characterized by additional presence of strong pro-inflammatory lipid mediators especially 
originating from the 5-LOX pathway such as LTB4 (Table 2). The increased COX1 and BLT1 
expression also confirmed an increased presence of inflammatory cells even in non-affected 
skin 4, 5, 8, 10. COX1 and ALOX12 were mainly present in keratinocytes in the skin and in 
influxed inflammatory cells (Figure 4, 42, 43).  
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PUFA-deficient diet is known to induce AD-like effects in mice 44-46, while in AD-patients and 
allergen sensitized mice various PUFAs are reduced in affected skin 47, 48. In our study n3/n6-
PUFA, several n3/n6-PUFA metabolite ratios and EPA-metabolite/AA-metabolite ratios were 
decreased in non-affected skin of AD-patients resulting in no resolvation of the current 
inflammatory status and even in a more vulnerable skin towards further inflammation. 
Linoleic acid deficiency was described to be of relevance in AD-patients 47, 48, here we further 
determined reduced percentile LA-metabolite ratios in non-affected skin of AD-patients 
(Figure 2B). We conclude that in AD-patients even a healthy looking skin is prone to a pro-
inflammatory status and pro-itch conditions 44, 45, 49. This general dysregulation of skin 
eicosanoid/docosanoid levels in non-affected skin, comparable to retinoid dysregulation in 
skin of AD-patients 28, indicates a general and systemic background of AD 7, 28, 35. Itch-
induced scratch response further results in epidermal barrier defects, bacterial infection and 
further inflammation of the skin mainly mediated via 5-LOX and leukotriene mediated 
pathways 8, 10. It seems that this altered itch/scratch signaling in non-affected skin, which is 
highly likely induced via a systemic disorder 35, 50, is of crucial importance for the progress 
and initiation of AD. These novel results are of high importance for prevention strategies 
against itch in this skin disease.  
 
In affected skin of AD-patients even a higher increase of pro-inflammatory eicosanoids 51, 
increased pro-inflammatory enzyme pathways and all calculated sums of LOX and COX was 
observed and a strong inflammatory background towards maintenance of chronic 
inflammatory conditions was present in AD. Compared to non-affected skin and even 
stronger in the affected skin the n3/n6-PUFA and several n3/n6-PUFA metabolite ratios were 
lower, while an increased ratio of pro-inflammatory vs. pro-resolving lipid mediators result in 
maintenance of this chronic inflammation and displaying no tendency of resolving and 
healing of these inflammatory conditions 45, 47, 48, 50, 52. Reduced levels of pro-resolving 
derivatives (LXA4 53/ MAR 54) and strong increased ratio of pro-inflammatory vs. pro-
resolving lipid mediators (Figure 2A) were also found in serum confirming this pro-
inflammatory and non-pro-resolving environment present in AD-patients (Table 1).  
 
A reduced expression of the leukotriene receptors (BLT1 and CYSLTR2), mainly transmitting 
pro-inflammatory signaling, was present in affected skin, which might indicate feedback 
mechanism 10. Pro-resolving activity was suggested to be mediated by 15-LOX signaling 
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resulting in the formation of pro-resolving lipid mediators 55-58. Indeed in non-affected skin 
and affected skin of AD-patients, especially in affected skin, the 15-LOX metabolites were 
increased but not resulting in increased levels of pro-resolving metabolites such as LXA4, 
RvE- and RvD-derivatives in the skin. A tendency for increased 15-HETE was confirmed in 
our study in affected skin (Table 2). This reduced 12-LOX/15LOX ratio indicates a biological 
feedback against these pro-inflammatory conditions in skin of AD-patients 55, 56. 
 
The biological meaning of increased 12-LOX pathways found in our study remains 
controversial. Various forms of 12/15-LOX are known and expressed in the skin with 
relevance for skin homeostasis and inflammatory response, reviewed in 42. 12/15-LOX 
expression is induced by either IFNγ (15-LOX2, 59) or IL4 (12/15-LOX, 60) mediated 
pathways and 12/15-LOX deficiency results in protection against allergic airway 
inflammation 55, 56. Recently, ALOX12B expression was even associated with retinoid 
signaling 61. 12-HETE, the major metabolite originating from AA, and further 12-LOX 
metabolites are transmitting pain and itch response 62, 63. 12-HETE is a ligand of PPARδ 64, a 
nuclear hormone receptor, which can transmit pro-inflammatory and hyperproliferative 
signaling present in atopic dermatitis and psoriasis 65-67. On the other hand, the ALOX12 and 
ALOX3 metabolites, hepoxilins and trioxilins, were shown to be potent PPARα agonists and 
important for barrier formation (reviewed in 42, 68).  
 
A second eicosanoid with a pivotal role is PGD2 4. It is described to induce pro-inflammatory 
response 69-71, but partly also acts as a pro-resolving derivative 72-74. PGD2 can initiate 
signaling via DP1 and DP2 mediated pathways, which may partly explain this pivotal role 4, 
75. While DP1 mainly mediates chemotaxis and pro-inflammatory signaling, DP2 induces 
inhibitory activity on inflammatory cell signaling and thereby mainly anti-inflammatory 
signaling, reviewed in 75. A new concept suggests that pro-inflammatory ligands may also 
induce a following induction of later pro-resolving activities and PGD2 as a major driver 
(reviewed in 4). Additionally PGD2 is also known to be a potent endogenous ligand of PPAR γ 
11, 76. 
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PPARα/γ-mediated signaling has been associated with anti-inflammatory signaling (reviewed 
in 16, 77, 78). FABPs attracts ligands like n3-PUFAs and promote PPAR-mediated signaling 18, 19 
just as various eicosanoid-derived ligands 11, 12. In our study in affected skin, the sum of the 
potent endogenous PPAR-agonists d15d12PGJ2, 12-KETE, 15-KETE, 13-KODE, PGD2, PGJ2 
and 4-HDHA 11, 17, 76, 79, 80 displayed tendencies or even significant increased levels in affected 
skin of AD-patients. The calculated sum of the concentrations of PPAR-ligands was increased 
in affected skin of AD-patients suggesting an anti-inflammatory feedback mechanism. Levels 
of PGD2, 15-KETE and 13-KODE found in affected skin of AD-patients were even sufficient 
for PPAR-activation. In opposite, reduced PPAR-expression was observed in affected skin of 
AD-patients, indicating a reduced ability to dampen inflammation and skin healing 13, 14, 
while in the non-affected skin the increased PPARγ-expression indicated an enabled anti-
inflammatory feedback. In summary, we observed increased calculated sums and sufficient 
concentration of PPAR-ligands for PPAR-mediated transactivation in affected skin, but 
reduced expression of PPARα and γ as well as PPAR-target gene expression levels, resulting 
in reduced PPAR-mediated signaling characterizing chronic inflammatory conditions present 
in affected skin of AD-patients.  
 
The major question is how a preventive and/or therapeutic strategy for atopic dermatitis 
with various approaches focusing on general strong anti-inflammatory treatments. 
Unfortunately eicosanoid–metabolism is mediated via the same cascade of enzymes for 
various PUFAs resulting in pro-inflammatory and pro-resolving metabolites 4, 6, 7, 52. Blocking 
one pathway may induce desired as well as detrimental effects. In addition mainly single 
compounds targeting one pathway are administered in current therapies. We suggest that a 
multiple compound treatment strategy at distinct time points during allergic response may 
be more beneficial. For a therapeutic approach, we specifically suggest a blocking of 
selective prostaglandin receptors with selective antagonists plus topical co-application of 
bioactive n3-originating precursors like HEPEs and HDHAs for pro-resolving lipid-mediators 
like resolvins, lipoxins, protectins and maresins. Unfortunately, the majorities of these 
suggested endogenous occurring lipid-mediators are extremely labile compounds and are 
not suitable for systemic and / or topical nutritional as well as pharmaceutical applications. 
In addition, our novel knowledge about the increased itch-markers in non-affected skin, 
points towards a systemic approach partly demonstrated by supplementation studies with 
DHA-enriched fish oil in AD-patients 81 as well as targeted anti-itch preventive topical 
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approach to non-affected skin areas. Currently, based on these knowledge, our group 
develops various approaches which can also be tested under clinical conditions. 
 
In summary, keeping in mind the limits from the low number of examined samples, a 
strongly decreased n3/n6-PUFAs, n3/n6-PUFA metabolite ratios, increased ratio of pro-
inflammatory vs. pro-resolving lipid mediators and strongly increased itch-mediators and 
increased pro-inflammatory cascade are hallmarks of a chronic inflammation present in the 
affected, but partly also in non-affected skin, of human AD-patients. The affected skin of 
AD-patients is indicated in comparison to the non-affected skin by additional an increased 5-
LOX pathway and especially LTB4 levels. 
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Tables: 
Table 1:  
H-SE (conc. in ng/ml) D-SE (conc. in ng/ml) Significance  
AA   314.8 ± 74.8  265.6 ± 168.4  0.67 
5-HETE   6.1 ± 5.8  0.5 ± 0.5  0.17 
8-HETE*  0.7 ± 0.3  0.4 ± 0.5  0.51 
11-HETE  1.0 ± 0.3  1.0 ± 0.8  1.00 
12-HETE  42.5 ± 11.1  99.6 ± 92.2  0.35 
15-HETE  1.6 ± 0.4  2.4 ± 2.1  0.57 
20-HETE  0.8 ± 0.4  2.1 ± 2.0  0.33 
LTB4*   3.3 ± 3.9  0.5 ± 0.6  0.29 
20-OH-LTB4*  0.1 ± <0.1  0.2 ± 0.3  0.43 
20-COOH-LTB4  0.9 ± 0.7  0.5 ± <0.1  0.37 
20-COOH-AA  0.8 ± 0.5  2.6 ± 2.6  0.29 
LTC4*   0.3 ± 0.2  0.2 ± 0.2  0.48 
PGD2   4.7 ± 2.2  6.8 ± 2.9  0.37 
PGE2   6.8 ± 0.8  6.2 ± 3.5  0.77 
d15d12PGD2*  1.1 ± 0.3  0.6 ± 0.6  0.25 
PGJ2*   0.3 ± 0.5  0.4 ± 0.2  0.76 
d15d12PGJ2*  <0.1 ± <0.1  0.1 ± <0.1  0.38 
TXB2   31.2 ± 10.7  52.5 ± 52.1  0.53 
8i-PGF2α  2.1 ± 2.4  2.6 ± 2.5  0.81 
PGF2α   0.8 ± 0.2  0.9 ± 0.7  0.75 
5-KETE   0.7 ± 0.5  1.0 ± 0.8  0.65 
12-KETE*  1.1 ± 1.9  3.3 ± 2.4  0.28 
15-KETE*  2.4 ± 2.1  0.1 ± <0.1  0.13 
LXB4*   0.1 ± <0.1  0.2 ± 0.1  0.40 
LXA4*   0.4 ± 0.1  0.1 ± <0.1  <0.01 
HXA3*   2.1 ± 2.2  1.4 ± 0.8  0.64 
HXB3*   0.6 ± 0.5  1.0 ± 1.6  0.74 
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EPA   81.7 ± 39.6  38.8 ± 35.8  0.24 
5-HEPE*  3.0 ± 2.6  0.1 ± 0.1  0.13 
8-HEPE   1.0 ± 0.4  1.1 ± 1.4  0.89 
12-HEPE  2.8 ± 1.7  3.8 ± 4.7  0.74 
15-HEPE*  0.4 ± 0.2  0.4 ± 0.3  0.75 
18-HEPE*  0.3 ± 0.5  1.4 ± 1.7  0.37 
LTB5*   0.5 ± 0.3  0.1 ± 0.1  0.05 
PGE3   0.8 ± 0.4  3.6 ± 3.0  0.18 
 
DHA   205.2 ± 79.9  70.4 ± 30.0  0.03 
4-HDHA*  5.8 ± 5.1  0.1 ± 0.1  0.12 
10-HDHA*  0.6 ± 0.4  0.3 ± 0.1  0.29 
14-HDHA  2.9 ± 1.9  1.8 ± 2.1  0.53 
17-HDHA*  1.2 ± 0.9  0.4 ± 0.5  0.27 
20-HDHA  0.6 ± 0.4  0.5 ± 0.2  0.66 
RvD1*   0.4 ± 0.5  0.1 ± <0.1  0.31 
RvD2   2.2 ± 2.1  0.4 ± <0.1  0.20 
MAR*   0.4 ± 0.1  0.1 ± <0.1  <0.01 
PD1*   0.3 ± 0.2  0.1 ± 0.1  0.12 
 
LA   365.2 ± 89.5  194.2 ± 173.4  0.43 
9-HODE  4.3 ± 1.6  4.6 ± 0.5  0.78 
13-HODE  5.1 ± 1.1  6.9 ± 0.9  0.04  
13-KODE  19.2 ± 7.5  14.7 ± 5.5  0.45 
 
The concentration of lipid mediators in serum samples from healthy volunteers (H-SE) (n=3) and patients with 
AD (D-SE) (n=3) were measured by HPLC-MS-MS. Results in ng/ml are expressed as mean ± SD. Numbers in 
bold letters are significantly different (P < 0.05, Mann Whitney test) and numbers in italic letters just identify a 
tendency of significance (p<0.1). Abbreviations see legend to figure 1. * For the marked substances values 
which were under the quantification limit of the used methodology of 0.2 ng/ml were replaced with a value of 
half of the detection limit (0.1 ng/ml). 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2: 
  H-SK   N-SK  A-SK   Significance  
  conc. in ng/g  conc. in ng/g conc. in ng/g  H:N  H:A  N:A 
 
AA  772.5  ± 83.0 1563.2 ± 353.4 1408.0 ± 427.2  0.02   0.05   0.65 
5-HETE  0.3  ± 0.1 0.8 ± 0.4 1.2 ± 0.1  0.08  <0.01   0.10 
8-HETE  0.7  ± 0.3 1.3 ± 0.4 6.2 ± 4.5  0.11  0.10  0.13 
11-HETE  0.8  ± 0.2 1.9 ± 0.8 2.1 ± 0.7  0.07  0.03   0.79 
12-HETE  35.0  ± 33.3 88.1 ± 60.8 70.1 ± 39.2  0.26  0.30  0.69 
15-HETE  5.5  ± 3.7 9.5 ± 3.2 118.3 ± 143.3  0.23  0.24  0.26 
20-HETE* 2.1 ± 0.8 7.2 ± 7.3 2.6 ± 2.5  0.29  0.77  0.35 
LTB4*  0.1 ± 0.1 0.5 ± 0.3 1.4 ± 0.6  0.10  0.01   0.04 
20-OH-LTB4* 0.2 ± 0.1 1.0 ± 1.4 1.9 ± 1.7  0.39  0.15  0.49 
20-COOH-LTB4 7.2 ± 8.0 12.1 ± 10.0 5.9 ± 4.1  0.54  0.82  0.38 
20-COOH-AA* 5.1 ± 5.9 2.4 ± 2.2 1.4 ± 2.0  0.50  0.36  0.57 
LTC4  0.9 ± 0.2 0.5 ± 0.2 0.5 ± 0.5  0.07  0.36  0.97 
PGD2  27.1 ± 14.7 104.5 ± 102.0 62.3 ± 40.1  0.26  0.23  0.54 
PGE2  36.8 ± 19.6 143.8 ± 66.1 66.1 ± 12.5  0.05   0.04   0.12 
d15d12PGD2 1.2 ± 0.5 2.4 ± 0.3 2.7 ± 1.6  0.01   0.18  0.74 
PGJ2*  0.1 ± 0.2 2.9 ± 1.9 2.1 ± 0.3  0.07  <0.01   0.51 
d15d12PGJ2* 0.1 ± 0.1 0.2 ± 0.2 0.1 ± 0.1  0.33  0.61  0.23 
TXB2*  2.0 ± 2.3 4.7 ± 3.8 5.7 ± 8.2  0.35  0.49  0.85 
8i-PGF2α* 3.7 ± 3.2 11.3 ± 4.9 6.9 ± 3.2  0.09  0.29  0.27 
PGF2α   3.3 ± 2.4 23.3 ± 13.0 8.6 ± 2.2  0.03   0.02  0.12 
5-KETE*  1.5 ± 1.4 0.5 ± 0.8 0.8 ± 0.7  0.32  0.45  0.64 
12-KETE* 4.7 ± 2.6 6.2 ± 6.0 10.5 ± 9.4  0.71  0.36  0.54 
15-KETE* 1.4 ± 1.2 4.8 ± 4.2 25.8 ± 16.6  0.24  0.06  0.10 
LXB4*  0.3 ± 0.3 0.9 ± 1.3 0.1 ± <0.1  0.45  0.38  0.34 
LXA4*  0.3 ± 0.1 0.5 ± 0.5 0.7 ± 0.5  0.49  0.23  0.68 
HXA3  2.0 ± 1.9 11.2 ± 9.5 9.1 ± 9.4  0.18  0.27  0.80 
HXB3  3.2 ± 4.3 5.6 ± 4.0 10.5 ± 8.3  0.50  0.25  0.42 
 
EPA  125.4 ± 57.2 98.3 ± 40.0 97.8 ± 21.8  0.54  0.48  0.99 
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5-HEPE*  0.1 ± 0.1 0.1 ± <0.1 0.3 ± 0.2  0.20  0.12  0.18 
8-HEPE*  1.9 ± 1.3 1.8 ± 2.4 5.1 ± 4.3  0.96  0.28  0.31 
12-HEPE 5.9 ± 4.5 9.4 ± 6.9 5.8 ± 0.6  0.50  0.96  0.41 
15-HEPE 2.0 ± 1.2 2.4 ± 1.0 10.0 ± 7.1  0.64  0.13  0.14 
18-HEPE* 5.5 ± 5.0 2.4 ± 1.0 2.7 ± 4.5  0.36  0.51  0.93 
LTB5*  0.2 ± 0.4 0.4 ± 0.6 0.7 ± 0.6  0.77  0.33  0.53 
PGE3  6.5 ± 9.8 2.3 ± 1.8 16.5 ± 15.4  0.51  0.40  0.19 
 
DHA  141.7 ± 37.3 114.7 ± 29.5 153.7 ± 46.0  0.38  0.74  0.28 
4-HDHA* 0.1 ± 0.1 0.2 ± 0.2 0.4 ± 0.1  0.57  <0.01   0.11 
10-HDHA* 0.2 ± <0.1 0.5 ± 0.2 1.1 ± 0.6  0.14  0.03  0.13 
14-HDHA 4.2 ± 2.8 8.3 ± 7.5 9.4 ± 6.7  0.43  0.28  0.86 
17-HDHA 2.1 ± 1.3 3.4 ± 0.8 33.9 ± 27.1  0.24  0.11  0.12 
20-HDHA* 0.4 ± 0.3 0.3 ± 0.3 0.7 ± 0.6  0.92  0.39  0.34 
RvD1*  0.5 ± 0.5 2.7 ± 3.4 0.2 ± 0.1  0.34  0.37  0.29 
RvD2  3.8 ± 5.0 5.1 ± 4.0 1.5 ± 0.5  0.74  0.48  0.20 
MAR*  0.4 ± 0.4 0.4 ± 0.2 0.3 ± 0.3  0.99  0.93  0.90 
PD1*  0.3 ± 0.5 0.3 ± 0.2 0.7 ± 0.2  0.81  0.29  0.04 
 
LA  247.9 ± 36.4 430.7 ± 179.9 311.4 ± 46.0  0.16  0.13  0.33 
9-HODE  31.2 ± 9.6 91.9 ± 72.0 59.7 ± 37.3  0.22  0.27  0.53 
13-HODE 54.0 ± 19.6 83.6 ± 23.1 211.0 ± 135.9  0.17  0.12  0.18 
13-KODE 146.4 ± 43.3 110.6 ± 64.3 377.7 ± 190.0  0.47  0.11  0.08 
 
The concentration of lipid mediators in skin samples from healthy volunteers (H-SK) (n=3), non-affected skin samples (N-SK) 
(n=3) and affected skin samples from patients with AD (A-SK) (n=3) were measured by HPLC-MS-MS. Results in ng/ml are 
expressed as mean ± SD. Numbers in bold letters are significantly different (P < 0.05, Mann Whitney test) and numbers in 
italic letters just identify a tendency of significance (p<0.1). * For the marked substances selected values which were under 
the quantification limit of the used methodology of 0.2 ng/g were replaced with a value of half of the detection limit (0.1 
ng/g). 
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Figure legends: 
 
Figure 1: Schematic diagram of derivatives which were mainly determined using 
our HPLC MS-MS competence. Derivatives which are more than 20% upregulated in 
serum of patients with AD in comparison to healthy controls are marked with red 
and derivatives which are more than 20% downregulated are marked with blue. 
Abbreviations: ALA - alpha-linolenic acid, EPA - eicosapentaenoic acid, DPA - 
docosapentaenoic acid, DHA - docosahexaenoic acid, LA - linoleic acid, GLA - 
gamma-linolenic acid, DHGLA - dihydro-gamma-linolenic acid, AA - arachidonic acid, 
5-HEPE - 5-hydroxy-eicosapentaenoic acid, 8-HEPE - 8-hydroxy-eicosapentaenoic 
acid, 12-HEPE - 12-hydroxy-eicosapentaenoic acid, 15-HEPE - 15-hydroxy-
eicosapentaenoic acid, 18-HEPE - 18-hydroxy-eicosapentaenoic acid, LTB5 - 
leukotriene B5, 4-HDHA - 4-hydroxy-docosahexaenoic acid, 10-HDHA - 10-hydroxy-
docosahexaenoic acid, 14-HDHA - 14-hydroxy-docosahexaenoic acid, 17-HDHA - 17-
hydroxy-docosahexaenoic acid, 20-HDHA - 20-hydroxy-docosahexaenoic acid, PD1 - 
protectin D1, RvD1 - resolvin D1, RvD2 - resolvin D2, 9-HODE - 9-hydroxy-10,12-
octadecadienoic acid, 13-HODE - 13-hydroxy-9,11-octadecadienoic acid, 13-KODE – 
13-oxo-9,11-octadecadienoic acid, 5-HETE - 5-hydroxy-eicosatetraenoic acid, 8-HETE 
- 8-hydroxy-eicosatetraenoic acid, 11-HETE – 11-hydroxy-eicosatetraenoic acid, 12-
HETE - 12-hydroxy-eicosatetraenoic acid, 15-HETE - 15-hydroxy-eicosatetraenoic 
acid, 20-HETE – 20-hydroxy-eicosatetraenoic acid, LTB4 - leukotriene B4, 20-OH-
LTB4 - 20-hydroxy-leukotriene B4, 20-COOH-LTB4 - 20-carbohydroxy-leukotriene B4, 
20-COOH-AA - 20-carbohydroxy- arachidonic acid, LTC4 - leukotriene C4, PGH2 - 
prostaglandin H2, PGD2 - prostaglandin D2, PGE2 - prostaglandin E2, PGF2α - 
prostaglandin F2α, PGJ2 - prostaglandin J2, PGE3 - prostaglandin E3, d15d12PGJ2- 
15-deoxy-Δ12,14-prostaglandin J2, d15d12PGD2 - 15-deoxy-Δ12,14-prostaglandin 
D2, TXB2 - thromboxane B2, 8i-PGF2α - 8-iso-prostaglandin F2α, 5-KETE - 5-oxo-
eicosatetraenoic acid, 12-KETE - 12-oxo-eicosatetraenoic acid, 15-KETE - 15-oxo-
eicosatetraenoic acid, LXB4 - lipoxin B4, LXA4 - lipoxin A4, HXA3 - hepoxilin A3, 
HXB3 - hepoxilin B3, MAR - maresin. 
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Figure 2: (A) Calculated sums and ratios of various eicosanoids, docosanoids and PUFAs 
(AA, EPA, DHA, LA). Sums are calculated from metabolites originating from AA, EPA, DHA, 
LA and from 5-LOX, 12-LOX, 15-LOX, COX and 8-hydroxylation (8-OH) pathways as well as 
summarized HETEs, HEPEs, HDHAs, HODEs. Ratios were calculated from PUFAs, HETEs, 
HEPEs, HDHAs, HODEs, summarised PUFA-metabolites as well as pro-inflammatory (LTB4, 
LTC4, PGD2, PGE2, PGF2, d15d12PGD2, TXB2 and 5-KETE) and pro-resolving (LXA4, LXB4, 
RvD1, RvD2, PD1, MAR) lipid mediators (pro-inf / pro-res) originating from AA, EPA, DHA 
and LA in affected (A-SK), non-affected skin (N-SK) of AD-patients compared to skin of 
healthy controls (H-SK) as well as serum of AD-patients (D-SE) in comparison to serum from 
healthy volunteers (H-SE). (B) The calculated amounts of AA-, DHA-, EPA- and LA-derived 
PUFA-metabolites were displayed as percentile amounts for affected (A-SK), non-affected 
skin (N-SK) of AD-patients compared to skin of healthy controls (H-SK). (C) Sum of itch-
mediators (12-HETE, LTB4, TXB2, PGE2, PGF2) in skin biopsies from affected (A-SK), non-
affected skin (N-SK) of AD-patients compared to skin of healthy controls (H-SK). (D) Ratio of 
summarised 12LOX / 15LOX metabolites like listed in table 1 and 2 and (E) calulated sums 
of PPAR-ligands (d15d12PGJ2, 12-KETE, 15-KETE, 13-KODE, PGD2, PGJ2 and 4-HDHA) in 
affected (A-SK), non-affected skin (N-SK) of AD-patients compared to skin of healthy 
controls (H-SK). Abbreviations: 5-LOX – 5-lipoxygenase, 8-OH – 8-hydroxylation pathway, 
12-LOX – 12-lipoxygenase, 15-LOX – 15-lipoxygenase, COX – cyclooxygenase. Other listed 
abbreviations see legend of figure 1.  
 
Figure 3: Calculated upregulation and downregulation of the normalized mRNA expression 
levels of various enzymes and receptors clustered and calculated for different functional 
metabolic pathways (5-LOX, 12/15-LOX, COX pathways, PPAR receptors and PPAR-target 
genes and fatty acid binding proteins) involved in PUFA-metabolite signaling in affected (A-
SK) (n=6) and non-affected skin (N-SK) (n=6) of AD-patients in comparison to healthy 
controls (H-SK) (n=6). 
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Figure 4: Expression of COX1 and ALOX12B in the skin from healthy controls and patients 
with atopic dermatitis. Representative immunohistochemical images of COX1 and ALOX12B 
staining in healthy (H-SK), non affected skin of AD-patients (N-SK) and affected skin of AD-
patients (A-SK). Strong presence of ALOX12B and COX1 proteins in epidermis is marked by 
black arrows, while strong presence of both proteins in the dermal infiltrating cells are 
marked by the green arrow. Bars, 100 μm.  
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